Core Insights - Cognition Therapeutics, Inc. is advancing its clinical-stage drug development focused on neurodegenerative disorders, particularly Alzheimer's disease, with a significant emphasis on precision medicine [1][4] Group 1: Clinical Developments - Dr. Mary Hamby will co-host a workshop at the Hanson Wade Neuroimmunology Drug Development Summit to discuss participant screening methods for clinical trials [1] - The Phase 2 'SHINE' study of zervimesine (CT1812) showed that participants with lower p-tau217 levels had a 95% better score on the ADAS-Cog 11 scale and 108% better on the MMSE scale compared to those on placebo [2][3] Group 2: Diagnostic Potential - Plasma p-tau217 assays can serve as a diagnostic tool to identify Alzheimer's patients who are most likely to benefit from therapies targeting beta amyloid, enhancing personalized treatment approaches [3] Group 3: Company Overview - Cognition Therapeutics is focused on developing small molecule therapeutics for age-related degenerative disorders, with zervimesine being investigated in clinical programs for dementia with Lewy bodies and Alzheimer's disease [4]
Cognition Therapeutics’ VP of Research Co-hosting Precision Medicine Workshop at the Neuroimmunology Drug Development Summit